The reporter learned from the Institute of Modern Physics of the Chinese Academy of Sciences that the IP-SAFE project superconducting linear accelerator, which was built by the Institute in conjunction with the Gansu Isotope Laboratory, has recently completed initial beam flow debugging to achieve pulse beam penetration. This indicates that China's first demonstration device that can mass-produce alpha radioactive isotopes such as actinium-225 and radium-223 already has basic production capacity. The full name of the IP-SAFE project is an “accelerator-based medical isotope drug development platform”, and it is one of the country's “14th Five-Year Plan” science and education infrastructure. The project relies on the technical accumulation and advantages of the Institute of Modern Physics of the Chinese Academy of Sciences in the fields of high-current superconducting linear accelerators, high-power targets, and isotope separation. It aims to achieve large-scale production of the world's scarce medical alpha isotopes — actinium-225 and radium-223, and focus on solving the situation where China has long relied on imports for such high-end medical nuclides.

The reporter learned from the Institute of Modern Physics of the Chinese Academy of Sciences that the IP-SAFE project superconducting linear accelerator, which was built by the Institute in conjunction with the Gansu Isotope Laboratory, has recently completed initial beam flow debugging to achieve pulse beam penetration. This indicates that China's first demonstration device that can mass-produce alpha radioactive isotopes such as actinium-225 and radium-223 already has basic production capacity. The full name of the IP-SAFE project is an “accelerator-based medical isotope drug development platform”, and it is one of the country's “14th Five-Year Plan” science and education infrastructure. The project relies on the technical accumulation and advantages of the Institute of Modern Physics of the Chinese Academy of Sciences in the fields of high-current superconducting linear accelerators, high-power targets, and isotope separation. It aims to achieve large-scale production of the world's scarce medical alpha isotopes — actinium-225 and radium-223, and focus on solving the situation where China has long relied on imports for such high-end medical nuclides.